VAXIMM today announced that the Company will participate in several upcoming events in the first quarter of 2018.
- Preclinical data in leukemia with oral T-cell immunotherapy VXM10 targeting PD-L1 to be presented at ASCO-SITC Clinical Immuno-Oncology Symposium
Basel (Switzerland) and Mannheim (Germany), January 18, 2018 - VAXIMM, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the Company will participate in several upcoming events in the first quarter of 2018.
ASCO-SITC Clinical Immuno-Oncology Symposium
January 25-27, 2018
San Francisco, CA, USA
The ASCO-SITC Clinical Immuno-Oncology Symposium is focused on clinical and translational research in immuno-oncology and the implications for clinical care. VAXIMM will present preclinical data with its oral T-cell immunotherapy development candidate VXM10. The poster, “Live attenuated oral Salmonella platform for effective T- and B-cell targeting of PD-L1,” summarizes the immunogenicity and anti-leukemia activity of VXM10 in an animal model, transformed with a eukaryotic expression plasmid encoding different variants of the murine PD-L1 protein.
The poster will be presented during Poster Session A on Thursday, January 25th at 11:30 AM - 1:00 PM and 5:30 PM - 6:30 PM PT. The abstract will be available online on January 22nd at abstracts.asco.org.
11th Annual European Life Sciences CEO Forum & Exhibition
February 26-27, 2018
Zurich, Switzerland
This biopharmaceutical industry forum will address the main challenges in investment, partnering and alliance management for 2018. In plenary sessions and therapeutics panels, keynote speakers will provide their insights which cover the macro picture as well as innovation in various therapeutic sectors. Click here for more information about this event.
Dr. Heinz Lubenau, Chief Operating Officer of VAXIMM, will participate in the “Platform Technologies and Novel Therapeutics” panel taking place on Monday, February 26th at 4:15 PM CET. In addition, he will give a corporate presentation. The presentation details will be posted on the Company’s website as soon as available.
12th Annual International Partnering Conference BIO-EUROPE Spring(R)
March 12-14, 2018
Amsterdam, The Netherlands
With a focus on European innovation and global collaboration, BIO-Europe Spring(R) is the premier springtime partnering conference bringing together executives from biotech, pharma and finance in the most innovative biopharma clusters in Europe. More information on this conference is available here. Dr. Heinz Lubenau will give a corporate presentation. The presentation details will be posted on the Company’s website as soon as available.
About VAXIMM:
VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target specific structures of the tumor. VAXIMM’s lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. VXM01 is currently in clinical development for several tumor types, including pancreatic, colorectal and brain cancer. In addition to VXM01, VAXIMM has a pipeline of complementary development candidates targeting different tumor structures. VAXIMM’s investors include BB Biotech Ventures, Merck Ventures, Sunstone Capital and BioMed Partners. VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company’s development activities. For more information, please see www.vaximm.com.
Contact:
VAXIMM AG
Dr. Heinz Lubenau
Tel.: +49 621 8359 687 0
Email: info@vaximm.com
Media Inquiries:
MC Services AG
Katja Arnold, Laurie Doyle
Tel: +49 89 210228 0
Email: vaximm@mc-services.eu
